➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Moodys
McKesson
Baxter
McKinsey

Last Updated: October 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,716,867

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,716,867
Title: Use of dexmedetomidine for ICU sedation
Abstract:The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated.
Inventor(s): Aantaa; Riku (Turku, FI), Bachand; Romeo (Mundelain, IL), Heinonen; Esa (Turku, FI)
Assignee: Orion Corporation (Espoo, FI)
Application Number:09/647,364
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,716,867
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 6,716,867

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,716,867

PCT Information
PCT FiledMarch 31, 1999PCT Application Number:PCT/FI99/00266
PCT Publication Date:October 07, 1999PCT Publication Number: WO99/49854

International Family Members for US Patent 6,716,867

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 015744   Start Trial
Austria 347359   Start Trial
Australia 3149499   Start Trial
Australia 754484   Start Trial
Bulgaria 104797   Start Trial
Bulgaria 64540   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
Mallinckrodt
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.